• By ICR Secretariat
  • Posted Thursday, April 15, 2021

Farxiga fails to achieve statistical significance in COVID-19 trial


AstraZeneca (AZ) announced this morning that its diabetes drug Farxiga was unable to hit the primary endpoints in a Phase III trial assessing the drug for the potential treatment of high-risk hospitalised COVID-19 patients.